Moderna Can't Invalidate Drug-Delivery Composition Patent
The Patent Trial and Appeal Board ruled Thursday that Moderna Therapeutics Inc. failed to invalidate claims in Arbutus Biopharma Corp.'s patent covering a drug-delivery composition as obvious or anticipated based on...To view the full article, register now.
Already a subscriber? Click here to view full article